Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
Your Fridays feeling awaits Make everyday feel like a Friday
Disclosure of interest: All authors nothing to disclose Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.05 - NEUROINTERVENTION P624 - ESOC25-1109 FRAILTY SURPASSES CHRONOLOGICAL AGE IN PREDICTING FUNCTIONAL OUTOCMES OF PATIENTS WITH AGED ABOVE 70 : A RETROSPECTIVE MULTINATIONAL COHORT THROMBECTOMY STUDY Joshua Yeo 1 , May Zin Myint 1 , Tsong-Hai Lee 2 , Volker Maus 3 , Sebastian Fischer 3 , Stefab Schob 4 , Davide Simonato 5 , Giacomo Cester 6 , Joseph D
When tesamorelin is the more appropriate choice Tesamorelin is typically the preferred agent when: Visceral adipose tissue is the primary treatment target, particularly with associated metabolic comorbidities A clinician is working within a framework that prioritises FDA-approved agents The patient has HIV-associated lipodystrophy, the only approved indication A robust evidence base is required for clinical decision-making For general somatopause-related concerns gradual changes in body composition, sleep quality, and recovery the CJC-1295/ipamorelin combination remains more commonly used, primarily because of its flexible dosing profile and the preserved pulsatile GH release pattern
Because the more I researched it, while understanding that I also have a 20 year history of being misdiagnosed and mis-prescribed all manner of anti-depressants, anti-anxiety medications and sleeping medications (until I got off all of it cold turkey on Dec 23, 2019), I also was left with an acutely sensitive brain
